Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile
Ali et al.,
Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile,
Journal of Pharmaceutical Research International, doi:10.9734/jpri/2020/v32i830468 (Dosing)
Review of the mechanisms of action, pharmacokinetics and toxicity of HCQ, recommending use as early as possible with a loading dose in 3-4 divided doses to minimize toxicity, and daily maintenance divided into two doses, continued until remission.
Ali et al., 29 May 2021, peer-reviewed, 8 authors.
Abstract: Journal of Pharmaceutical Research International
32(8): 29-43, 2020; Article no.JPRI.56916
ISSN: 2456-9119
(Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919,
NLM ID: 101631759)
Optimizing the Use of Hydroxychloroquine in the
Management of COVID-19 Given Its
Pharmacological Profile
Ahmed S. Ali1*, Mahran S. Abdel-Rahman2, Riyadh S. Almalikil3,
Abir S. Mohamed4, Khalid A. Alfaifi5, Abdelbabgi El. Fadil6,
Nagla A. El-Shitany7,8 and Huda M. Alkreathy1
1
Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, KSA.
2
Department of Pharmacology, Faculty of Medicine, Assiut University, Egypt.
3
Department of Pharmacology, Faculty of Pharmacy, Umm Al-qura University, KSA.
4
Department of Internal Medicine, Faculty of Public Health and Tropical Medicine,
Jazan University, KSA.
5
Department of Pharmacy, Medical Services Directorate, Taif, KSA.
6
Department of Medical Microbiology and Parasitology, Faculty of Medicine,
King Abdulaziz University, KSA.
7
Department of Pharmacology and Toxicology, Faculty of Pharmacy,
King Abdulaziz University, KSA.
8
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Authors’ contributions
All authors actively participated in this reference research and major work. Author ASA designed the
idea in cooperation with author MSAR. Author RSA early joined the team to organize communication
between researchers. He prepares the introduction. Author ASA assumed full supervision of the
research with the assistance of all colleagues author MSAR prepared the side effects of the drug he
also reviewed all that colleagues author ASM reviewed all clinical issues related to COVID 19 patients
and their management she described in details cardiac toxicity of HCQ. Author AEF revised all
sections related to the novel virus description and epidemiology. Author KAA collected and reviewed
the pharmacokinetics of HCQ and its integration with the efficacy and safety issues. Author NAES
participated actively in explaining the mechanism of HCQ. She also provided the summary and
conclusion. Author HMA provided huge effort to edit the review, in a professional way regarding all
aspects, language, reference and connoting ideas etc.
Article Information
DOI: 10.9734/JPRI/2020/v32i830468
Editor(s):
(1) Dr. Jongwha Chang, University of Texas, USA.
Reviewers:
(1) Victor B. Oti, Nasarawa State University, Nigeria.
(2) Pichon Maxime, University Hospital of Poitiers, France.
(3) Celso Ramos, National Institute of Public Health, Mexico.
Complete Peer review History: http://www.sdiarticle4.com/review-history/56916
Review Article
Received 23 April 2020
Accepted 12 May 2020
Published 29 May 2020
_____________________________________________________________________________________________________
*Corresponding author: E-mail: Profahmedali@gmail.com;
ORCID: 0000-0002-3341-8177
Ali et al.; JPRI, 32(8): 29-43, 2020; Article no.JPRI.56916
ABSTRACT
After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary
to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning
some medications is the best, fastest and most reliable option for treating patients with the new
coronavirus without delay. One of these drugs was an old antimalarial drug, hydroxychloroquine.
The current review aimed to explore its potential mechanism, as well as its pharmacokinetics and
toxicity, in an attempt to suggest a..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit